Blumenstein, B., Saad, F., Hotte, S., Chi, K. N., Eigl, B., Gleave, M., & Jacobs, C. (2013). Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen. Blackwell Science Inc.
Chicago Style CitationBlumenstein, Brent, Fred Saad, Sebastien Hotte, Kim N. Chi, Bernhard Eigl, Martin Gleave, i Cindy Jacobs. Reduction in Serum Clusterin Is a Potential Therapeutic Biomarker in Patients With Castration-resistant Prostate Cancer Treated With Custirsen. Blackwell Science Inc, 2013.
Cita MLABlumenstein, Brent, et al. Reduction in Serum Clusterin Is a Potential Therapeutic Biomarker in Patients With Castration-resistant Prostate Cancer Treated With Custirsen. Blackwell Science Inc, 2013.